Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis for EW stock:

Technical Analysis The stock is currently trading at $68.75, showing bearish signals with RSI at 34.29 (oversold territory). The stock is trading below its 20-day moving average of $72.27, indicating a short-term downtrend.

Recent Events A significant event occurred where Katie Szyman, who previously headed Edwards Lifesciences' critical care division, was appointed as CEO of Masimo. This leadership transition suggests stability in Edwards' former executive team members securing prominent positions in the industry.

Analyst Sentiment Recent analyst actions show mixed opinions:

• Wolfe Research downgraded to Sell with $60 target (-14.11% downside) on January 16, 2025, citing concerns about transcatheter aortic valve replacement market share
• B of A Securities upgraded to Strong Buy with $90 target (+21.77% upside) in December 2024
• Goldman Sachs maintains Strong Buy with $90 target (+24.26% upside)

Technical Levels Key Fibonacci levels indicate:

• Resistance: R1 at $73.10, R2 at $74.48
• Support: S1 at $68.61, S2 at $67.23
• Current price ($68.75) is testing S1 support level

Based on the technical analysis, bearish analyst downgrade, and current market positioning near support levels, it would be prudent to SELL EW stock at current levels. The stock could see further downside toward the $67 level before finding strong support.

Based on the provided data and market analysis, here's the price prediction for Edwards Lifesciences (EW) stock in 2025:

EW stock is projected to reach $85-90 by end of 2025, driven by the company's strong growth in Transcatheter Aortic Valve Replacement (TAVR) segment which is expected to contribute $4.1-4.4 billion in 2025 sales with 5-7% growth. The company's recent leadership changes and strategic focus on structural heart solutions provide additional upside potential.

The stock is currently trading at a 5% premium to fair value, suggesting limited near-term upside until earnings catch up to valuations over the next few quarters.

The S1 support level for EW Stock is $68.61 ,The R1 resistant level for EW Stock is $73.1.

As of the end of day on 2025-01-24, the price of EW Stock was $68.75.

The target price for EW Stock according to analyst rating is 78.67, with the highest price target at 90.00 and the lowest at 68.00. Analysts have a Moderate Buy rating on EW Stock overall.

The market cap of EW is $40.7B.

Based on the provided data, I'll analyze whether EW is overvalued through multiple valuation metrics and recent developments.

Valuation Analysis: Edwards Lifesciences' valuation metrics have significantly decreased in Q3 2024, with P/E dropping to 25.4x from 41.1x in Q1, and EV/EBITDA declining to 19.1x from 30.0x, suggesting improved valuation levels.

Recent Developments: The company recently sold its critical care division to Becton Dickinson for $4.2B in September 2024, which has impacted its valuation metrics and business focus.

Analyst Sentiment: Recent analyst actions show mixed views, with Wolfe Research downgrading to Sell with a $60 target due to concerns about TAVR mortality data, while B of A Securities upgraded to Strong Buy with a $90 target.

Growth Metrics: The company maintains strong profitability with gross margins above 80% and healthy net margins around 26%, indicating efficient operations despite recent business restructuring.

Conclusion: At current levels, EW is not overvalued considering its industry position, strong margins, and recent strategic divestiture. The significant reduction in valuation multiples from early 2024 suggests a more reasonable valuation.

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It also develops hemodynamic and noninvasive brain and tissue oxygenation monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. It conducts operations worldwide and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. It sells products that are used to treat advanced cardiovascular disease in all regions.

Based on the provided data and analysis, here is the price prediction for Edwards Lifesciences (EW) stock by 2030:

Edwards Lifesciences stock is projected to reach $95-100 by 2030, driven by its strong position in structural heart therapies and expanding TMTT segment which is expected to contribute $2 billion in revenue by 2030. The company's focus on innovation in TAVR technology and strategic expansion in emerging markets supports this growth trajectory. The current technical indicators and analyst consensus showing a moderate buy rating with near-term price targets around $75-76 provide a solid foundation for this longer-term projection.

EW has a total of 19800 employees.